<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744495</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01440-49</org_study_id>
    <nct_id>NCT02744495</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery</brief_title>
  <acronym>PONVACS</acronym>
  <official_title>Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery (PONVACS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Privé de Parly II - Le Chesnay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Privé de Parly II - Le Chesnay</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of postoperative nausea and vomiting risk factors assessment after
      cardiac surgery. We designed a randomized controlled study comparing standard care (no risk
      factor assessment and no intervention) with prophylaxis of postoperative nausea and vomiting
      after cardiac surgery in high risk patients. Prophylaxis of postoperative nausea and vomiting
      by betamethasone (4mg) and/or droperidol (0.625mg) immediately after cardiac surgery,
      depending on risk factors (if risk score is over 2) in the intervention arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients planned to undergo cardiac surgery were screened for inclusion. Inclusion criteria
      are as follow: Non emergent cardiac surgery; Age &gt; 18 years; Affiliation to French Social
      Security; Approval of participation to the study; at the exclusion of: Pregnancy ; Contra
      indication to antiemetics; Chronic usage of antiemetics; and Emergent or complicated surgery.

      Risk factors for postoperative nausea and vomiting were collected and patients were
      randomized by cluster into two arms.

      Control: No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk
      factors were not available for practicians.

      Intervention: Preoperative collection of postoperative nausea and vomiting risk factors
      available for practicians. Prophylaxis if risk score is over 2. Prophylaxis of postoperative
      nausea and vomiting by betamethasone (4mg) and/or droperidol (0.625mg) immediately after
      cardiac surgery, depending on risk factors in the intervention arm.

      All outcomes are assessed at 48 hours of surgery:

      Primary: occurrence of postoperative nausea or vomiting Secondary: number of postoperative
      nausea and vomiting with visual assessment scale (VAS), and antiemetics used for treatment;
      postoperative pain (VAS) with number of analgesics used; postoperative discomfort (VAS).

      Safety data: side effects and QT corrected intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>48hour</time_frame>
    <description>postoperative nausea and vomiting as a categorical variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of postoperative nausea and vomiting</measure>
    <time_frame>48hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting (VAS)</measure>
    <time_frame>48hour</time_frame>
    <description>Suffering from postoperative nausea and vomiting by visual assessment scale (VAS). VAS is a 100 point scale: 0 indicate absence of nausea or vomiting; 100 indicate maximal nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain (VAS)</measure>
    <time_frame>48hour</time_frame>
    <description>VAS is a 100 point scale: 0 indicate absence of pain; 100 indicate maximal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative discomfort (VAS)</measure>
    <time_frame>48hour</time_frame>
    <description>VAS is a 100 point scale: 0 indicate absence of discomfort; 100 indicate maximal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiemetics (treatment)</measure>
    <time_frame>48hour</time_frame>
    <description>Number of antiemetics used as a treatment for postoperative nausea or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesics</measure>
    <time_frame>48hour</time_frame>
    <description>Number of Analgesics used at 48h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>48hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval</measure>
    <time_frame>48hour</time_frame>
    <description>Pre and postoperative QTc (corrected) intervals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Postoperative Vomiting</condition>
  <condition>Postoperative Nausea</condition>
  <condition>Postoperative Emesis</condition>
  <arm_group>
    <arm_group_label>postoperative nausea and vomiting risk factors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.</description>
    <arm_group_label>postoperative nausea and vomiting risk factors</arm_group_label>
    <other_name>Celestene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droperidol</intervention_name>
    <description>Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.</description>
    <arm_group_label>postoperative nausea and vomiting risk factors</arm_group_label>
    <other_name>Droleptan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non emergent cardiac surgery

          -  Age &gt; 18 years

          -  Affiliation to French Social Security

          -  Approval of participation to the study

        Exclusion Criteria:

          -  Pregnancy

          -  Contra indication to antiemetics

          -  Chronic usage of antiemetics

          -  Emergent or complicated surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parly2</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Privé de Parly II - Le Chesnay</investigator_affiliation>
    <investigator_full_name>Sébastien CHAMPION</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>corticoids</keyword>
  <keyword>droperidol</keyword>
  <keyword>antiemetics</keyword>
  <keyword>Postoperative Vomiting</keyword>
  <keyword>Postoperative Nausea</keyword>
  <keyword>Postoperative Emesis</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Droperidol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On demand</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

